PharmaMar
Biopharmaceutical company specializing in the discovery, development, and commercialization of marine-derived drugs for cancer and other serious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $10.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 215 % | (15 %) | (15 %) | (19 %) | 11 % | 16 % | 41 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 58 % | 45 % | 28 % | 3 % | 12 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 51 % | 40 % | 25 % | 1 % | 15 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 20 % | 31 % | 43 % | 63 % | 59 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
PharmaMar is a Spanish biopharmaceutical company headquartered in Colmenar Viejo, Madrid, specializing in the discovery, development, and commercialization of innovative oncology drugs derived from marine resources. Founded in 1986, PharmaMar has established itself as a global leader in marine-based drug research, maintaining a robust pipeline and commercial portfolio focused on cancer therapeutics.
The company is structured around three main business segments: Oncology, Diagnostics, and RNA interference. Its oncology division is the core of its operations, with a focus on developing antitumor drugs sourced from marine organisms. PharmaMar’s most notable marketed products include Yondelis (trabectedin), used for advanced soft tissue sarcoma and relapsed ovarian cancer; Zepzelca (lurbinectedin), approved for metastatic small cell lung cancer; and Aplidin (plitidepsin), developed for multiple myeloma. These drugs leverage unique mechanisms of action, such as inhibiting RNA polymerase II, to target cancer cells in ways traditional therapies cannot.
PharmaMar’s Diagnostics segment, through its subsidiary Genomica, develops molecular diagnostic kits, including those for infectious diseases like COVID-19. The company’s RNA interference unit, led by subsidiary Sylentis, is advancing gene-silencing therapies for retinal and other diseases.
With a workforce of approximately 500 employees, PharmaMar operates internationally, with subsidiaries and commercial activities across Europe, the United States, and other regions. The company is publicly traded on the Madrid Stock Exchange and is a component of the IBEX 35 index, reflecting its significance in the Spanish and European biotech landscape.
Keywords: marine-derived drugs, oncology, antitumor, Yondelis, Zepzelca, Aplidin, RNA interference, diagnostics, molecular testing, gene silencing, biopharmaceutical, Spain, cancer therapy, innovative research, global operations, IBEX 35